Effects of platelet-activating factor receptor antagonist (PAFRA) on selected inflammatory and biochemical parameters in lipopolysaccharide-induced rat endotoxemia model

Platelet Aktive edici Faktör (PAF), sepsisde yangısel reaksiyonlara karışan birçok hücre tarafından üretilen immun sistemin önemli bir fosfolipid mediyatörüdür. Bu deneysel çalışmada amacımız, lipopolisakkarit (LPS) uygulanan sıçanlarda biyokimyasal ve yangısel bozukluklar üzerine PAF reseptör antagonisti (PAFRA)’nın rolünü araştırmaktı. Total 32 adet yetişkin erkek sıçan dört eşit gruba ayrıldı: grup 1 kontrol (C) olarak hizmet etti. Grup 2’deki hayvanlara intravenöz LPS (1.6 mg/100 g, Escherichia Coli, 0.111:B4) verildi. Grup 3’de 0.9% serum fizyolojik enjeksiyonundan 2 dak. önce PAFRA (10mg/kg) intraperitoneal olarak enjekte edildi. Grup 4’de, LPS uygulamasından 2 dak. önce PAFRA uygulandı. Kan örnekleri uygulamadan sonraki 6.saatte toplandı. LPS (grup 2), serum TNF-a, IL-6 ve IL1β seviyesi, CRP, LDH, AST, ALT, kreatinin, BUN, kolesterol, trigliserit konsantrasyonunu önemli düzeyde artırdı, platelet sayısı, glikoz, total protein ve albumin seviyesini önemli oranda düşürdü. Ayrıca kontrol grupla karşılaştırıldığında LPS grupta lökopeni ve diferensiyal lökosit sayısında önemli değişiklikler mevcuttu (P

Lipopolisakkarit ile indüklenen rat endotoksemi modelinde bazı yangısel ve biyokimyasal parametreler üzerine platelet Aktive edici Faktör reseptör antagonisti (PAFRA)’nin etkileri

Platelet-activating factor (PAF) is a significant phospholipid mediator of the immune system produced by a veriety of cells involved in inflammatory reactions in sepsis. In this experimental study, our aim was to investigate the role of PAF receptor antagonist (PAFRA) on biochemical and inflammatory disturbances in lipopolysaccharide (LPS)-treated rats. A total of 32 adult male Wistar rats were divided into four equal groups: Group 1 (control group, C) was treated with 0.9% saline. Group 2: LPS was injected intravenously (1.6 mg/100 g), Group 3 received PAFRA treatment (10 mg/kg) 2 min before 0.9% saline injection, Group 4 received PAFRA treatment 2 min before endotoxin treatment. Blood samples were collected 6 h after treatment. LPS (Group-II) caused statistically significant increases in serum TNF-a, IL-6 and IL1β levels, CRP, LDH, AST, ALT, creatinine, BUN, cholesterol, triglyceride concentration, and caused statistically significant decreases in platelet count, glucose, total protein and albumin levels. Also, when compared to control group leukopenia and significant changes in the leukocyte differential were evident. In group 4, PAFRA inhibited serum TNF-α and IL1β levels, leukopenia compared with the group 2 (P<0.05). However, there were no significant differences in the other parameters between the two groups. The results demonstrate that at the administered dose and route, PAFRA has a slight effect in the pathogenesis of endotoxemia.

PDF

___

1. Møller S, Laigaard F, Olgaard K, Hemmingsen C: Effect of 1,25- dihydroxy-vitamin D3 in experimental sepsis. Int J Med Sci, 4, 190-195, 2007.
2. Çöl R, Durgun Z: Effect of recombinant interleukin-10 on some haematological and biochemical parameters in a rat endotoxaemic model. Acta Vet Hung, 59, 237-245, 2011.
3. Hryszko T, Inaba K, Ihara H, Suzuki Y, Mogami H, Urano T: Nafamostat attenuated the impairment of fibrinolysis in animal sepsis model by suppressing the increase of plasminogen activator inhibitor type 1. J Trauma, 60, 859-864, 2006.
4. Çöl R, Durgun Z: Effect of vasoactive intestinal peptide (VIP) on cytokine levels and haemostatic and biochemical parameters in a rat endotoxaemic model. Bull Vet Inst Pulawy, 56, 63-67, 2012.
5. van Westerloo DJ, Giebelen IAJ, Meijers JCM, Daalhuisen J, de Vos AF, Levi M, van der Poll T: Vagus nerve stimulation inhibits activation of coagulation and fibrinolysis during endotoxemia in rats. J Thromb Haemost, 4, 1997-2002, 2006.
6. Gonzalez-Rey E, Chorny A, Robledo G, Delgado M: Cortistatin, a new antiinflammatory peptide with therapeutic effect on lethal endotoxemia. J Exp Med, 203, 563-571, 2006.
7. Cheng T, Mathews K, Abrams-Ogg A, Wood D: The link between inflammation and coagulation: influence on the interpretation of diagnostic laboratory tests. Compend Contin Educ Vet, 33, E1-E12, 2011.
8. Jeschke MG, Rensing H, Klein D, Schubert T, Mautes AE, Bolder U, Croner RS: Insulin prevents liver damage and preserves liver function in lipopolysaccharide-induced endotoxemic rats. J Hepatol, 42, 870-879, 2005.
9. Fernández-Martínez E, Morales-Ríos MS, Pérez-Alvarez V, Muriel P: Immunomodulatory effects of thalidomide analogs on LPS-induced plasma and hepatic cytokines in the rat. Biochem Pharmacol, 68, 1321-1329, 2004.
10. Grypioti AD, Kostopanagiotou G, Demopoulos CA, Roussos A, Mykoniatis M: Platelet activating factor (PAF) antagonism with ginkgolide B protects the liver against acute injury. importance of controlling the receptor of PAF. Dig Dis Sci, 53 (4): 1054-1062, 2008.
11. Koltai M, Hosford D, Guınot P, Esanu A, Braquet P: PAF, a review of its effects, antagonists and possible future implications (Part 1). Drugs, 42, 9- 29, 1991.
12. Suputtamongkol Y, Intaranongpai S, Smith MD, Angus B, Chaowagul W, Permpikul C, Simpson JA, Leelarasamee A, Curtis L, White NJ: A double-blind placebo-controlled study of an infusion of lexipafant (Platelet- activating factor receptor antagonist) in patients with severe sepsis. Antimicrob Agents Chemother, 44, 693-696, 2000.
13. Horkheimer I, Schuster DP: The role of platelet-activating factor in sepsis: A bench-to-bedside review. Advances In Sepsis, 2 (1): 2-7, 2002.
14. Yost CC, Weyrich AS, Zimmerman GA: The platelet activating factor (PAF) signaling cascade in systemic inflammatory responses. Biochimie, 92 (6): 692-697, 2010.
15. Xia SH, Hu CX, Zhao ZL, Xia GD, Di Y: Significance of platelet activating factor receptor expression in pancreatic tissues of rats with severe acute pancreatitis and effects of BN52021. World J Gastroenterol, 13 (21): 2992-2998, 2007.
16. Travers J, Pei Y, Morin SM, Hood AF: Antiinflammatory activity of the platelet-activating factor receptor antagonist A-85783. Arch Dermatol Res, 290 (10): 569-573, 1998.
17. SPSS: SPSS Release 15.0 Statistical packet program, SPSS for Windows. SPSS Inc., Chicago, IL. 2006.
18. Hopper, K, Bateman, S: An updated view of hemostasis: mechanisms of hemostatic dysfunction associated with sepsis. J Vet Emerg Crit Care, 15, 83-91, 2005.
19. Han SJ, Ko HM, Choi JH, Seo KH, Lee HS, Choi EK, Choi IW, Lee HK, Im SY: Molecular mechanisms for lipopolysaccharide-induced biphasic activation of nuclear factor-kappa B (NF-kappa B). J Biol Chem, 277 (47): 44715-44721, 2002.
20. Moreno SE, Alves-Filho JC, Rios-Santos F, Silva JS, Ferreira SH, Cunha FQ, Teixeira MM: Signaling via platelet-activating factor receptors accounts for the impairment of neutrophil migration in polymicrobial sepsis. J Immunol, 177 (2): 1264-1271, 2006.
21. McManus LM, Pinckard RN: PAF, a putative mediator of oral inflammation. Crit Rev Oral Biol Med, 11, 240-258, 2000.
22. Asakura H, Takahashi Y, Kubo A, Ontachi Y, Hayashi T Omote M, Arahata M, Kadohira Y, Maekawa M, Yamazaki M, Morishita E, Takami A, Yoshida T, Miyamoto K, Nakao S: Immunoglobulin preparations attenuate organ dysfunction and hemostatic abnormality by suppressing the production of cytokines in lipopolysaccharide-induced disseminated intravascular coagulation in rats. Critical Care Medicine, 34, 2421-2425, 2006.
23. Iba T, Miyasho T: Danaparoid sodium attenuates the increase in inflammatory cytokines and preserves organ function in endotoxemic rats. Critical Care, 12, R86, 2008.
24. Mathiak G, Grass G, Herzmann T, Luebke T, Zetina CC, Boehm SA, Bohlen H, Neville LF and Hoelscher AH: Caspase-1-inhibitor ac-YVAD-cmk reduces LPS lethality in rats without affecting haematology or cytokine responses. Br J Pharmacol, 131, 383-386, 2000.
25. Ishii S, T Nagase, F Tashiro, K Ikuta, S Sato, I Waga, K Kume, J Miyazaki, T Shimizu: Bronchial hyperreactivity, increased endotoxin lethality and melanocytic tumorigenesis in transgenic mice overexpressing platelet-activating factor receptor. EMBO J, 16, 133-142, 1997.
26. Tang, HM, Teshima DY, Lum BKB: Effects of the PAF antagonist Befafant and L-659,989 in endotoxic and septic shock. Drug Dev Res, 29, 216-221, 1993.
27. Ogata M, Nandate K, Kawasaki T, Kawasaki C, Ozaki M, Shigematsu A: A platelet activating factor receptor antagonist inhibits cytokine production in human whole blood by bacterial toxins and live bacteria. Anesth Analg, 98 (6): 1767-1772, 2004.
28. Lo CJ, Cryer HG, Fu M, Kim B: Endotoxin-induced macrophage gene expression depends on platelet-activating factor. Arch Surg, 132, 1342-1347, 1997.
29. Ishii S, Nakamura M, Waga I, Kume K, Izumi T, Shimizu T: Cloning and characterization of a murine platelet-activating factor receptor gene. Adv Exp Med Biol, 407, 347-355, 1997.
30. Im SY, Han SJ, Ko HM, Choi JH, Chun SB, Lee DG, Ha TY, Lee HK: Involvement of nuclear factor kappa B in platelet-activating factor-mediated tumor necrosis factor-alpha expression. Eur J Immunol, 27, 2800–2804, 1997.
31. Wang H, Tan X, Chang H, Gonzalez-Crussi F, Remick DG, Hsueh W: Regulation of platelet-activating factor receptor gene expression in vivo by endotoxin, plateletactivating factor and endogenous tumour necrosis factor. Biochem J, 322, 603-608, 1997.
32. Diaz Padilla N, Bleeker WK, Lubbers Y, Rigter GM, Van Mierlo GJ, Daha MR, Hack CE: Rat C-reactive protein activates the autologous complement system, Immunology, 109, 564-571, 2003.
33. Çöl R, Keskin E, Atalay B: Effect of pentoxifylline on endotoxin-induced haemostatic disturbances in rabbits. Acta Vet Hung, 53, 325-335, 2005.
34. Yang H, Li QW, Han Z S, Hu JH, Li WY, Liu ZB: Recombinant human antithrombin expressed in the milk of non-transgenic goats exhibits high efficiency on rat DIC model. J Thromb Thrombolysis, 28, 449-457, 2009.
35. Zhou W, Chao W, Levine BA, Olson MS: Role of plateletactivating factor in hepatic responses after bile duct ligation in rats. Am J Physiol, 263, G587- G592, 1992.
36. Coker A, Coker I, Huseyinov A, Sokmen S, Karademir S: Is mannitol effective against platelet-activating factor (PAF)-induced liver damage in obstructive jaundice? Hepatogastroenterology, 48, 1134-1137, 2001.
37. Yang Y, Nemoto EM, Harvey SA, Subbotin VM, Gandhi CR: Increased hepatic platelet activating factor (PAF) and PAF receptors in carbon tetrachloride induced liver cirrhosis. Gut, 53, 877-883, 2004.
38. Grypioti AD, Theocharis SE, Papadimas GJ, Demopoulos CA, Papadopoulou-Daifoti Z, Basayiannis AC, Lykoniatis LG: Platelet-Activating Factor (PAF) involvement in acetaminophen- induced liver toxicity and regeneration. Arc Toxicol, 79, 466-474, 2005.
39. Yazar E, Col R, Uney K, Atalay B, Elmas M, Tras B: Effect of pentoxifylline on biochemical parameters in endotoxaemic New Zealand White Rabbits. Bull Vet Inst Pulawy, 48, 297-299, 2004.
40. Memon RA, Grunfeld C, Moser AH, Feingold KR: Tumor necrosis factor mediates the effects of endotoxin on cholesterol and triglyceride metabolism in mice. Endocrinology, 132, 2246-2253, 1993.
41. Fraunberg P, Schaefer S, Werdan K, Walli AK, Seidel D: Reduction of circulating cholesterol and apolipoprotein levels during sepsis. Clin Chem Lab Med, 37, 357-362, 1999.
42. Al-Dughaym AM: Some endotoxin-induced clinical and biochemical changes in plasma of camels (Camelus dromedarius). Vet Res Commun, 28, 711-718, 2004.
43. Inarrea P, Gomez-Cambronero J, Nieto M, Sanchez Crespo M: Characteristics of the binding of plateletactivating factor to platelets of different animal species. Eu J Pharmacol, 105, 309-315, 1984.
44. Rabinovici R, Esser KM, Lysko PG, Yue T, Griswold DE, Hillegass LM, Bugelski PJ, Hallenbeck JM, Feuerstein G: Priming by platelet-activating factor of endotoxin-induced lung injury and cardiovascular shock. Circ Res, 69, 12-25, 1991.
45. van Devender SJH, Buller HR, ten Cate JW, Aareden LA, Hack CE, Sturk A: Experimental endotoxemia in humans: Analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood, 76, 2520-2526, 1990.
46. Ding Z, Li S, Wu Z: Mechanisms of endothelial cell-dependent leukocyte adhesion stimulated by platelet-activating factor. Inflammation, 16 (2): 179- 186, 1992.
47. Schmidt H, Ebeling D, Bauer H, Bŏhrer H, Gebhard MM, Martin E: Influence of the platelet-activating factor receptor antagonist BN52021 on endotoxin-induced leukocyte adherence in rat mesenteric venules. J Surg Res, 60 (1): 29-35, 1996.
48. Beyer AJ, Smalley DM, Shyr YM, Wood JG, Cheung LY: PAF and CD18 mediate neutrophil infiltration in upper gastrointestinal tract during intra- abdominal sepsis. Am J Physiol, 275, G467, 1998.
49. Garland RC, Sun D, Zandi S, Xie F, Faez S, Tayyari F, Frimmel SAF, Schering A, Nakao S, Hafezi-Moghadam A: Noninvasive molecular imaging reveals role of PAF in leukocyte-endothelial interaction in LPS-induced ocular vascular injury. FASEB J, 25, 1284-1294, 2011.
50. Moreno SE, Alves-Filho JC, Rios-Santos F, Silva JS, Ferreira SH, Cunha FQ, Teixeira MM: Signaling via platelet-activating factor receptors accounts for the impairment of neutrophil migration in polymicrobial sepsis. Immunol, 177 (2): 1264-1271, 2006.
51. Schmidt H, Ebeling D, Bauer H, Böhrer H, Gebhard MM, Martin E: Influence of the platelet-activating factor receptor antagonist BN52021 on endotoxin-induced leukocyte adherence in rat mesenteric venules. J Surg Res, 60, 29-35, 1996.
52. Coughlan AF, Hau H, Dunlop LC, Berndt MC, Hancock WW: P-selectin and platelet-activating factor mediate initial endotoxin-induced neutropenia. J Exp Med, 179, 329-334, 1994.
53. Defaux JP, Thonier F, Baroggi N, Etienne A, Braquet P: Involvement of platelet-activating factor (PAF) in endotoxin- or ischaemia-induced intestinal hyperpermeability in the rat. J Lipid Mediat: 7, 11-21, 1993.